Company news
Exact Therapeutics As (OSL:EXTX) news
Exact Therapeutics As news releases on 6ix. Latest, Sep 4, 2026: EXACT Therapeutics publishes shareholder information regarding the delisting
Press releases & updates
EXACT Therapeutics publishes shareholder information regarding the delisting
September 4, 2026
EXACT Therapeutics AS - Issuance of share options
August 31, 2026
EXACT Therapeutics : Oslo Stock Exchange approves application to delist EXACT Therapeutics’ shares
July 2, 2026
EXACT Therapeutics AS - Removal from trading
June 30, 2026
EXACT Therapeutics: Announces webcast regarding strategic intent to delist the company's shares from listing on Euronext Growth, Oslo
June 1, 2026
EXACT Therapeutics: Strategic intent to delist the company's shares from listing on Euronext Growth, Oslo
May 29, 2026
EXACT Therapeutics AS: Share capital increase registered
March 26, 2026
EXACT Therapeutics : Notice of Extraordinary General Meeting for EXACT Therapeutics March 13, 2026
March 13, 2026
EXACT Therapeutics : First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer
March 3, 2026
EXACT Therapeutics AS: Notice of extraordinary general meeting
February 27, 2026
EXACT Therapeutics AS: Warrants exercise
February 27, 2026
EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program
February 11, 2026
EXACT Therapeutics: Global investor call regarding the ongoing warrants exercise program
February 6, 2026
EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB
February 5, 2026
EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants
January 27, 2026
EXACT Therapeutics : Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants
January 27, 2026
EXACT Therapeutics AS: New option program and receipt of share options by primary insiders
November 24, 2025
EXACT Therapeutics first half 2025 interim results
September 25, 2025
EXACT Therapeutics : announces grant of core patent in the U.S.
September 15, 2025
EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer
June 24, 2025
EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer
May 20, 2025